Keytruda

Keytruda improves survival in first-line oesophageal cancer

The phase 3 KEYNOTE-590 trial evaluated Keytruda (pembrolizumab) in combination with chemotherapy in first-line oesophageal cancer. ... Currently, Bristol Myers Squibb’s rival checkpoint inhibitor Opdivo (nivolumab) is Keytruda’s only potential

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

Merck &Co’s checkpoint inhibitor Keytruda (pembrolizumab) currently holds much of the NSCLC market, although the drug failed to show benefit in SCLC when added to chemotherapy.

Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC

Tyvyt’s major rival is Merck &Co’s Keytruda (pembrolizumab), which holds approvals across a range of NSCLC indications. ... Keytruda has quickly been established as the new standard of care in NSCLC, after data from the KEYNOTE-189 study found that

Tecentriq combo fails in advanced triple negative breast cancer

TNBC is an important niche for Roche’s checkpoint inhibitor, in a class that is otherwise dominated by Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab). ... Despite the fail in TNBC, Keytruda is far ahead of its rivals in terms of revenues,

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

decline. Despite the NSCLC market being largely dominated by Merck &Co’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]